# Evaluation of the efficacy and safety of intravenous infusion of ferric derisomaltose in the treatment of iron deficiency anemia: a single-center retrospective analysis

## TL;DR

This study compares the effectiveness and safety of ferric derisomaltose and iron sucrose in treating iron deficiency anemia, finding ferric derisomaltose to be more effective and safer.

## Contribution

The study provides new clinical evidence on the superior efficacy and safety of ferric derisomaltose over iron sucrose for treating IDA.

## Key findings

- Ferric derisomaltose showed significantly higher HGB improvement than iron sucrose at all time points (P<0.01).
- 98.7% of patients with ferric derisomaltose achieved HGB increase >20 g/L within 4 weeks, compared to 75.9% with iron sucrose.
- Ferric derisomaltose had fewer mild adverse reactions and no severe infusion-related issues.

## Abstract

探讨缺铁性贫血（IDA）患者应用异麦芽糖酐铁注射液对比蔗糖铁注射液治疗的临床疗效及安全性。

选取2021年6月至2023年3月期间收治的缺铁性贫血患者120例，应用异麦芽糖酐铁注射液静脉补铁治疗，观察患者治疗前后HGB提升的有效性和安全性。同时与同期病房应用蔗糖铁补铁患者临床疗效及安全性进行对比。

两组患者基线HGB相当。治疗12周内，异麦芽糖酐铁组提升HGB水平高于蔗糖铁，各个时间差异均具有统计学意义（均P<0.01），治疗4周患者HGB提升超过20 g/L比例更高（98.7％对75.9％）。治疗过程中，异麦芽糖酐铁组发生轻度不良反应比例略低于蔗糖铁组，两组均无严重不良输液反应发生，输注治疗过程中患者耐受性良好，无注射部位疼痛及色素沉着等不良反应。

IDA患者应用异麦芽糖酐铁治疗疗效满意，具有见效迅速、疗效确切、安全性高的优点，值得临床广泛应用。